Organisation paid for research Program year 2025 Source: CMS Open Payments

Illinois CancerCare PC

Neither a doctor nor a teaching hospital

Research payments

$393,090

110 payments

Through program year 2025, Illinois CancerCare PC is reported as receiving $393,090 in research payments, across 110 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$8,416	10
2024	Research	$6,763	5
2023	Research	$216,268	68
2022	Research	$10,250	13
2021	Research	$69,480	6
2020	Research	$68,419	4
2019	Research	$13,494	4

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $246,411 88 payments
AbbVie, Inc. $78,980 7 payments
Pfizer Inc. $63,799 5 payments
Organon LLC $1,404 1 payment
F. Hoffmann-La Roche AG $1,000 2 payments
Novartis Pharmaceuticals Corporation $674 1 payment
Daiichi Sankyo Inc. $522 5 payments
Celgene Corporation $300 1 payment

Studies the money was for Research payments · program years 2019–2025

Tiragolumab Tecentriq VS Durvalumab in Unresectable Stage III Nsclc $82,163 18 payments
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) $69,480 6 payments
1Lm SCLC Tecentriq Lurbinectedin $62,404 21 payments
A Phase I Dose Escalation and Expanded Cohort Study of Pf06821497 in the Treatment of Adult Patients With Relapsedrefractory Small Cell Lung Cancer SCLC Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL $47,669 1 payment
Phii Placebo Controlled of Tiragolumab and Atezo in Nsclc $31,391 10 payments
Atezolizumab Carboplatin Etoposide Tiragolumab Or Placebo in 1L Es SCLC $25,131 13 payments
A Phase I Dose Escalation and Expanded Cohort Study of Pf06821497 in the Treatment of Adult Patients With Relapsedrefractory Small Cell Lung Cancer SCLC Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL $16,130 4 payments
Neoadjuvant Nsclc $13,148 11 payments
PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc $12,270 1 payment
Phase III Ipatasertib Plus Abiraterone in McRpc 1St Line $10,377 3 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $1,404 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.